Tamtam Try Tamtam free
Stevanato Group logo

Stevanato Group account plan

glass containers and components

At a glance

Stevanato Group makes drug containers, delivery devices and pharma equipment in Italy: €1,186.3 million FY2025 revenue, 6,010 employees.

Stevanato Group, based in Piombino Dese (Padua) and listed on the NYSE as STVN since July 2021, supplies drug containment (syringes, cartridges, vials), drug delivery devices, diagnostic consumables and pharmaceutical manufacturing equipment. It serves more than 700 companies, including 23 of the top 25 pharmaceutical companies, from 13 manufacturing plants in Italy, Germany, Slovakia, Brazil, Mexico, China, the United States and Denmark. FY2025 revenue was €1,186.3 million, up 7.4% reported and 9.1% at constant currency, with net profit of €139.8 million and Adjusted EBITDA of €298.0 million (25.1% margin); it had 6,010 employees at 31 December 2025. The founding family controls it through Stevanato Holding S.r.l., which holds about 73.73% of share capital and 93.09% of voting rights; Franco Stevanato is Chairman and CEO.

Business units

Strategic priorities

Shift the mix to high-value solutions
High-value solutions reached 46.0% of revenue in 2025 (38.3% in 2024) and are guided at 47% to 48% of revenue for 2026, with capacity focused on EZ-fill® and premium syringes.
Grow in biologics beyond GLP-1s
The CEO calls biologics' share of BDS "our most important KPI"; non-GLP-1 biologics grew over 30% in Q3 2026, and of more than 9,000 injectable assets in the pipeline, over 60% are biologics.
Build a drug delivery device business
Proprietary platforms Alina®, Deora™ and Aidaptus® plus device contract manufacturing; a liraglutide therapy using the Alina® pen was approved in several European countries in 2026, and Alina® capacity in Germany is being expanded.
Expand in North America
North America grew 17.2% to €362.1 million in 2025 (30.5% of revenue); the Fishers, Indiana plant is to be fully ramped by end-2028.
Return Engineering to profitable growth
A business optimization plan launched in 2024 moves activities from Denmark to Italy and right-sizes the structure; management is assessing the dilutive visual inspection and assembly activities.
Margin expansion and positive cash flow
Capital Markets Day targets of 29% to 30% EBITDA margin are reaffirmed as the trajectory, and free cash flow is expected to be positive in 2027.

Latest results

In Q3 2026, revenue rose 8% to €326.1 million (8% organic): BDS external revenue grew 10% to €294.0 million while Engineering fell 12% to €32.0 million. Adjusted EBITDA increased 14% to €88.8 million, a 27.2% margin, and net profit rose 16% to €41.8 million. GLP-1 therapies fell to about 17% to 18% of revenue, while non-GLP-1 biologics grew over 30%. Over nine months revenue was €901.6 million against €839.8 million. Full-year 2026 guidance was maintained at revenue of €1.260-1.280 billion, adjusted EBITDA of €335.0-345.2 million and adjusted diluted EPS of €0.60-0.62; management expects lower GLP-1 volumes in 2027 and low-single-digit growth that year.

Investments and deals

EZ-fill® capacity in Latina and Fishers
2025 capex was €294.9 million, of which €100.8 million in Latina, Italy and €65.6 million in Fishers, Indiana; new RTU 400 cartridge lines in Latina are to generate revenue from 2027.
Fishers, Indiana plant
Commercial production since 2024, up to 565,000 sq ft; BARDA committed up to about $95 million for vial capacity. It broke even at gross-profit level in Q3 2026 with about 50% of capacity installed.
Molding and device assembly
€66.4 million of 2025 capex went to plastic injection molding and assembly for IVD and devices; contract manufacturing of auto-injectors for a large U.S. client is to start at end-2026 or early 2027.
Bologna Engineering site
A new facility near Bologna was acquired in Q4 2025 for Engineering (€5.0 million of 2025 capex).
Sale of Balda C. Brewer
The California contract manufacturer of consumables and point-of-care diagnostic parts was sold in Q2 2026, with €12.2 million of one-off costs; 2026 capex is now €230-240 million.

Challenges and risks

Lower GLP-1 volumes in 2027
Lower volumes than previously expected, tied to one customer and to Nexa® syringes, are expected to moderate growth to low-single digits in 2027.
Engineering below expectations
Order conversion is delayed and Q3 2026 Engineering gross margin was 10.2%; the segment remains dilutive to corporate margin.
Customer concentration
The ten largest customers made 53.6% of 2025 revenue and one customer 12%.
Energy costs and tariffs
Higher European gas and energy prices weighed on Q3 2026 margins, and U.S. tariffs of 15% apply on goods shipped from Italy.
Plant ramp-up costs
Start-up costs for Fishers and Latina were €6.7 million in the first nine months of 2026, and ramp-up inefficiencies are a named risk.

What leadership says

“where there is an injection, Stevanato wants to be in”

Franco Stevanato, Chairman and CEO · Fourth Quarter and Full Year 2025 Financial Results Conference Call (4 March 2026)

“confident in our ability to grow low-single digits next year, based on what we know today.”

Franco Stevanato, Chairman and CEO · Third Quarter 2026 Results press release (3 November 2026)

“good business, but they remain dilutive to our corporate margin”

Franco Stevanato, Chairman and CEO · Third Quarter 2026 Financial Results Conference Call (3 November 2026), on visual inspection and assembly

“8 years to develop and launch on the market this Alina® product”

Franco Stevanato, Chairman and CEO · Second Quarter 2026 Financial Results Conference Call (4 August 2026)

Where a supplier can help

Plant ramp-up and automation
Tied to the Latina and Fishers investments and their ramp-up costs: suppliers of cleanroom, validation, automation and maintenance services can help bring lines to full output by end-2028.
Energy management
Tied to the energy-cost challenge: European gas and energy prices hit Q3 2026 margins, so energy procurement and efficiency offers fit the plants in Italy and Germany.
Device contract manufacturing inputs
Tied to the drug delivery device priority: scale-up of Alina® and contract manufacturing in Germany and Fishers needs molding, components and assembly partners.
Engineering order conversion
Tied to the Engineering challenge: tools that shorten long technical sales cycles and project execution could support the optimization plan.
Biologics customer acquisition
Tied to the biologics priority and customer concentration: sales intelligence on biotech and biosimilar programs can widen a base where ten customers make 53.6% of revenue.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Stevanato Group?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Stevanato Group

What does Stevanato Group do?

It makes pharmaceutical-grade glass drug containers such as pre-fillable syringes, cartridges and vials, drug delivery devices, diagnostic consumables and the machinery used to make and inspect them, for pharmaceutical, biotech and diagnostic companies.

What is Stevanato Group's revenue?

FY2025 revenue was €1,186.3 million, up 7.4% reported, and 2026 guidance is €1.260-1.280 billion.

How many employees does Stevanato Group have?

It had 6,010 employees at 31 December 2025, about 58% of them in Italy.

What is Stevanato Group's strategy?

Grow high-value solutions such as EZ-fill®, Nexa® and Alba®, expand in biologics and drug delivery devices, build capacity in Latina and Fishers, and restore Engineering's profitability.

Who leads Stevanato Group?

Franco Stevanato is Chairman and CEO and Marco Dal Lago is CFO; the family holding company holds 93.09% of voting rights.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)